正海生物 (300653.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	347.8M	364.1M	363.2M	413.7M	433.2M
Cost of Revenue	46.9M	51.4M	44.9M	41.8M	48.9M
Gross Profit	300.8M	312.7M	318.3M	371.9M	384.4M
Operating Expenses
R&D Expense	57.1M	57.3M	39.5M	44.0M	37.5M
SG&A Expense	—	—	—	—	—
General & Admin Expense	36.4M	34.8M	28.3M	26.9M	29.6M
Selling & Marketing Expense	141.9M	142.3M	119.6M	106.3M	116.9M
Other Expenses	—	—	—	—	—
Total Operating Expenses	241.4M	239.3M	190.8M	180.7M	187.1M
Cost and Expenses	288.4M	290.7M	235.7M	222.5M	235.9M
Operating Income (EBIT)	75.2M	89.2M	152.5M	218.6M	212.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	74.1M	88.1M	152.4M	218.4M	212.1M
Income Tax Expense	3.6M	5.7M	17.7M	27.4M	26.7M
Bottom Line
Net Income	70.5M	82.4M	134.6M	191.0M	185.4M
Earnings from Cont. Ops	70.5M	82.4M	134.6M	191.0M	185.4M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	70.5M	82.4M	134.6M	191.0M	185.4M
Per Share
Basic EPS	CN¥0.39	CN¥0.46	CN¥0.75	CN¥1.06	CN¥1.28
Diluted EPS	CN¥0.39	CN¥0.46	CN¥0.75	CN¥1.06	CN¥1.28
Revenue Per Share	CN¥1.89	CN¥2.03	CN¥2.02	CN¥2.30	CN¥2.99
Shares
Basic Shares Outstanding	184.4M	179.2M	179.5M	180.1M	144.9M
Diluted Shares Outstanding	184.4M	179.2M	179.5M	180.1M	144.9M
Profitability Metrics
EBITDA	—	112.0M	175.3M	239.5M	231.9M
D&A	—	22.8M	22.8M	20.9M	19.8M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026